Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis

November 4, 2013 08:33 (CET)

LUND, Sweden, Nov. 4, 2013 (GLOBE NEWSWIRE) --

Active  Biotech  (NASDAQ  OMX NORDIC: ACTI)
announced  today  that  its  partner  Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA)  will  initiate  a  further  clinical  trial,  LIBRETTO,  to  evaluate the
efficacy,  safety and tolerability of two doses of oral laquinimod (0.6 and 1.2
mg/day),  compared to  interferon beta-1a, in  patients with relapsing remitting
multiple  sclerosis. Primary  endpoint of  the study  will be brain atrophy. For
further  details please see  www.clinicaltrials.gov where the  trial will appear
during this week.

About laquinimod
Laquinimod  is an oral, investigational, CNS-active immunomodulator with a novel
mechanism  of action being developed for the treatment of relapsing-remitting MS
(RRMS).  The  global  Phase  III  clinical  development  program evaluating oral
laquinimod  in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase
III  laquinimod trial, CONCERTO, is evaluating  two doses of the investigational
product  (0.6mg and 1.2mg) in approximately  1,800 patients for up to 24 months.
The  primary outcome measure will be time to confirmed disability progression as
measured by the EDSS.

In  addition to the  MS clinical studies,  laquinimod has concluded  Phase II of
development  for  Crohn's  disease  and  lupus  nephritis.   Further studies are
planned  to determine the effectiveness of  laquinimod in treating patients with
Huntington's disease and Alzheimer's disease.

About Active Biotech
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In  addition,  laquinimod  has  concluded  Phase  II development for Crohn's and
Lupus.  The company also has one additional project in clinical development, the
orally  administered compound paquinimod  (57-57) for systemic sclerosis. Please
visit www.activebiotech.com for more information.



For further information:

Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson@activebiotech.com

  Active Biotech AB (Corp. Reg. No. 556223-9227)
  Box 724, SE-220 07 Lund
  Tel: +46 46 19 20 00
  Fax: +46 46 19 11 00

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act
This  press release  contains certain  forward-looking statements. Such forward-
looking  statements  involve  known  and  unknown risks, uncertainties and other
important   factors   that  could  cause  the  actual  results,  performance  or
achievements  of the company, or industry results, to differ materially from any
future  results,  performance  or  achievement  implied  by  the forward-looking
statements.  The company does not undertake any obligation to update or publicly
release   any   revisions  to  forward-looking  statements  to  reflect  events,
circumstances or changes in expectations after the date of this press release.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was provided to the media for publication 08:30 am CET on November 4, 2013.

Active Biotech's partner Teva initiates a further clinical trial : http://hugin.info/1002/R/1740139/584195.pdf

[HUG#1740139]